[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356461-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356461-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","quality-of-life-measurement-in-parp-inhibitor-trials-of-epithelial-ovarian-cancer-what-do-we-know","Quality of Life Measurement in PARP Inhibitor Trials of Epithelial Ovarian Cancer - What Do We Know?","","Epithelial ovarian cancer (EOC) remains a major global health burden, and relapse within two years is common even after advances in surgery and chemotherapy. Poly(ADP-ribose) polymerase inhibitors (PARPi) have improved progression-free survival, but their effects on health-related quality of life (HRQoL) are not fully defined. Patient-reported outcomes (PROs) are crucial for capturing physical, emotional, and social well-being. This review synthesizes trial evidence, addresses methodological heterogeneity, and identifies gaps to guide future QoL-centered endpoint design in ovarian cancer research.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/quality-of-life-measurement-in-parp-inhibitor-trials-of-epithelial-ovarian-cancer-what-do-we-know/356461/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/quality-of-life-measurement-in-parp-inhibitor-trials-of-epithelial-ovarian-cancer-what-do-we-know/356461.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are health-related quality of life (HRQoL) outcomes important in PARP inhibitor trials for epithelial ovarian cancer?","Question",{"text":63,"@type":64},"PARPi improve progression-free survival, yet their influence on patients’ physical, emotional, and social well-being needs clearer characterization. Patient-reported outcomes help quantify these HRQoL effects.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which clinical trials are referenced as demonstrating increased attention to quality-of-life (QoL) endpoints?",{"text":68,"@type":64},"The review cites trials including SOLO1, NOVA, and ARIEL3 as examples where QoL endpoints have gained recognition.",{"name":70,"@type":61,"acceptedAnswer":71},"What limitations make it difficult to compare QoL results across trials?",{"text":72,"@type":64},"Heterogeneity in the QoL tools used and differences in endpoints limit cross-trial comparisons.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356461,1790284071,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":124,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Quality of Life Measurement in PARP Inhibitor Trials of Epithelial Ovarian Cancer – What Do We Know?  \nCancer Control Volume 33: 1-10 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/10732748251385617](DOI: 10.1177/10732748251385617)  \n[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)  \nSarita Kumari, MBBS, MD, DNB, MCh 1 􀀁, Kovuri Umadevi, MBBS, MD, DNB2, and Dola Sundeep, PhD3  \nAbstract  \nEpithelial ovarian cancer (EOC), dominated by high-grade serous carcinoma, continues to impose a heavy global burden, particularly in low- and middle-income countries. Although advances in surgery and chemotherapy have extended survival, relapse within 2 years remains common, underscoring the need for novel strategies. Poly adenosine diphosphate ribose polymerase inhibitors (PARPi) have transformed maintenance therapy by prolonging progression-free survival, yet their inﬂuence on health-related quality of life (HRQoL) is less well characterized. Patient-reported outcomes (PROs) serve as key tools for evaluating the impact of treatment on physical, emotional, and social well-being. Trials including SOLO1, NOVA, and ARIEL3 demonstrate the increasing recognition of QoL endpoints, though heterogeneity in tools and endpoints limits cross-trial comparisons. Several gaps persist including limited data collection beyond disease progression. This review integrates evidence from published studies, highlights methodological challenges, and proposes directions for future work, emphasizing the centrality of patient-centered outcomes in advancing precision medicine for ovarian cancer. The evidence underscores the imperative of designing trials that incorporate QoL as a core endpoint, ensuring meaningful beneﬁts for patients in both clinical and real-world settings.  \nKeywords  \nepithelial ovarian cancer, high-grade serous carcinoma, PARP inhibitors, health-related quality of life, QoL metrics  \nReceived: June 16, 2025; revised: September 5, 2025; accepted: September 22, 2025.  \nEpithelial Ovarian Cancer – an Emerging Pandemic  \nIn 2022, global estimates suggested over 320,000 new cases of ovarian cancer and more than 200,000 related deaths.1 It is eighth most common cancer among women and also the eighth most common cause of death from cancer. According to GLOBOCAN projection, by 2050, the number of cases diagnosed with ovarian cancer (OC) will increase by 55% and the number of women dying from ovarian cancer will increase by almost 70% .2 Overall survival is well below other cancers affecting women (3) . There is a wide variation in the 5-year survival between countries mainly due to the quality of care provided. 5-year survival ranges between 36%–46% in  \n1 Department of Gynaecologic Oncology, Max Institute of Cancer Care, Max Super Speciality Hospital, Dwarka, India  \n2Department of Pathology, Osmania Medical College and Hospital, Hyderabad, India  \n3Biomedical Research Laboratory, Department of Electronics and Communication Engineering, Indian Institute of Information Technology Design and Manufacturing (IIITDM), Kurnool, India  \nCorresponding Authors:  \nSarita Kumari, MBBS, MD, DNB, MCh, Department of Gynaecologic Oncology Max Institute of Cancer Care, Max Super Speciality Hospital, Dwaraka 110075, India.  \nEmail: [sarita2325@gmail.com](sarita2325@gmail.com)  \nKovuri Umadevi, MBBS, MD, DNB, Department of Pathology, Osmania Medical College and Hospital, Hyderabad 500095, India.  \nEmail: dr.umadevik113@gmai[l.com](l.com)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use,  \nreproduction and distribution of the work without further permission provided the original work is attributed as speci","cbCaittqf4leeaW2","https://ap.wps.com/l/cbCaittqf4leeaW2","pdf",592921,"English","# Epithelial Ovarian Cancer – an Emerging Pandemic\n## What is Quality of Life?","[{\"question\":\"Why are health-related quality of life (HRQoL) outcomes important in PARP inhibitor trials for epithelial ovarian cancer?\",\"answer\":\"PARPi improve progression-free survival, yet their influence on patients’ physical, emotional, and social well-being needs clearer characterization. Patient-reported outcomes help quantify these HRQoL effects.\"},{\"question\":\"Which clinical trials are referenced as demonstrating increased attention to quality-of-life (QoL) endpoints?\",\"answer\":\"The review cites trials including SOLO1, NOVA, and ARIEL3 as examples where QoL endpoints have gained recognition.\"},{\"question\":\"What limitations make it difficult to compare QoL results across trials?\",\"answer\":\"Heterogeneity in the QoL tools used and differences in endpoints limit cross-trial comparisons.\"}]","Quality of Life Measurement in PARP Inhibitor Trials of Epithelial Ovarian Cancer - What Do We Know? | PDF",1790125416,25,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec67edfd7fb2ab92ebd33b78badb6553.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8bc365101e6e5f80f280f92f68be27a6.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c19ade09caf1000f673948b5fa09299.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5613c257c73e8f45d1e2b87adca2aa07.webp",980,1268]